A Bioequivalence Study Comparing HIP0901 Capsule With Lipidilsupra Tablet

Open-label, Randomized Comparative Study to Evaluate the Pharmacokinetic Characteristics of Fenofibric Acid Between Lipidilsupra Tablet and HIP0901 Capsule in Healthy Male Subjects

The purpose of this study is to evaluate pharmacokinetics and safety after oral administration of HIP0901 capsules and Lipidilsupra tablets.

Inclusion Criteria:

• Healthy male volunteers, age between 20 and 45
• Informed of the investigational nature of this study and voluntarily agree to participate in this study
• Weight>50kg, BMI of >18kg/m2 and <27kg/m2 subject

Exclusion Criteria:

• Acute disease within 28 days prior to start of study drug administration
• Use of any prescription medication within 14 days prior to Day 1
• Use of any medication within 7 days prior to Day 1
• Has a severe medical history of hypersensitivity to fibric acid derivative
• Participation in another clinical study within 30 days prior to start of study drug administration